Skip to main content
OpenTrials

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

2,606 public trials 492 recruiting studies
Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Recruiting

Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA

NCT07620275

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Biotherapeutic Department of Chinese PLA General Hospital Beijing, Beijing Municipality, China
  • Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University Beijing, China
  • National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin, China
View Trial Details
Recruiting

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

NCT05231629

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Columbia University New York, United States
  • Oregon Health and Science University Portland, Oregon, United States
View Trial Details
Recruiting

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

NCT06918002

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • CHU Amiens Amiens, France
  • CHU Angers Angers, France
  • Ch Annecy Genevois Annecy, France
  • Centre Hospitalier d'Argenteuil Victor Dupouy Argenteuil, France
View all 64 locations
View Trial Details
Recruiting

Collection of Tissue Samples for Cancer Research

NCT00900198

Conditions
Blood Protein Disorders, Bone Marrow Diseases, Cardiovascular Diseases, +18 more
Locations
  • UC Davis Sacramento, California, United States
  • University of Colorado, Denver Aurora, Colorado, United States
  • Emory University Atlanta, Georgia, United States
  • Indiana University - Purdue Indianapolis, Indiana, United States
View all 17 locations
View Trial Details
Recruiting

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

NCT04508790

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • City of Hope at Seacliff Huntington Beach, California, United States
  • City of Hope at Antelope Valley Lancaster, California, United States
  • City of Hope at Long Beach Elm Long Beach, California, United States
View Trial Details
Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

NCT02693535

Conditions
Advanced Solid Tumors, Blood Protein Disorders, Cardiovascular Diseases, +16 more
Locations
  • University of Alabama at Birmingham Comprehensive Cancer Center Birmingham, Alabama, United States
  • Cancer Treatment Centers of America-Phoenix Phoenix, Arizona, United States
  • Sutter Auburn Auburn, California, United States
  • Sutter Alta Bates Berkeley, California, United States
View all 181 locations
View Trial Details
Recruiting

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06988488

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Yale New Haven Hospital-Smilow Cancer Center New Haven, Connecticut, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • University of Texas MD Anderson Cancer Center Houston, Texas, United States
View all 22 locations
View Trial Details
Recruiting

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06297226

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • UCLA Hematology/Oncology - Westwood (Building 200 Suite 214) Los Angeles, California, United States
View all 52 locations
View Trial Details

Related conditions